Smoldering multiple myeloma associated with a acquired von Willebrand syndrome, successfully treated by daratumumab, lenalidomide and dexamethasone

被引：0
|
作者：
Iarossi, Michael [1 ]
Vekemans, Marie-Christiane Madeleine [2 ]
Weynants, Nicolas [3 ]
Hermans, Cedric [1 ]
机构：
[1] St Luc Hosp, St Lambert, Belgium
[2] Univ Catholique Louvain UCLouvain, Dept Internal Med, Brussels, Belgium
[3] Hop Arlon, Arlon, Belgium
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-427
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 50 条
  • [21] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
  • [22] Daratumumab as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy
    Mathew Thomas, Vinay
    Gilreath, Jeffrey A.
    Newton, Shawn
    Smock, Kristi J.
    Lim, Ming Y.
    HAEMOPHILIA, 2021, 27 (04) : E563 - E566
  • [23] Daratumumab, Bortezomib, and Dexamethasone for Previously Treated Multiple Myeloma
    Huang, Shang-Xiao
    Luo, Peng-Hui
    Wang, Han-Lei
    Mo, Dun-Chang
    Huang, Jian-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (14) : 2667 - 2668
  • [24] Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial
    Kumar, Shaji K.
    Alsina, Melissa
    Laplant, Betsy
    Badros, Ashraf Z.
    Abdallah, Al-Ola
    Abonour, Rafat
    Asmus, Erik J.
    Dhakal, Binod
    Rosenbaum, Cara A.
    Egan, Daniel
    Bhutani, Manisha
    Jakubowiak, Andrzej
    Durie, Brian G. M.
    BLOOD, 2022, 140 : 1830 - 1832
  • [25] M-protein-related necrobiotic granuloma in a multiple myeloma patient treated with daratumumab, lenalidomide and dexamethasone
    Bertuglia, Giuseppe
    Bringhen, Sara
    Bruno, Benedetto
    Impala, Giorgia Andrea
    D'Agostino, Mattia
    BRITISH JOURNAL OF HAEMATOLOGY, 2024,
  • [26] B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.
    Nadeem, Omar
    Redd, Robert
    Mo, Clifton Craig
    Laubach, Jacob
    Prescott, Julia
    Metivier, Amada
    Davie, Christine
    Bertoni, Meredith
    Murphy, Elizabeth
    Sheehan, Brian
    Tague, Kelsey
    Shrestha, Hira
    Medina, Rebekah
    Distaso, Alexandra
    Leblebjian, Houry
    Richardson, Paul G.
    Ghobrial, Irene M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Belch, Andrew
    White, Darrell
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Sutherland, Heather J.
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Bahlis, Nizar J.
    Chari, Ajai
    O'Rourke, Lisa
    Wu, Kaida
    Schecter, Jordan M.
    Casneuf, Tineke
    Chiu, Christopher
    Soong, David
    Sasser, A. Kate
    Khokhar, Nushmia Z.
    Avet-Loiseau, Herve
    Usmani, Saad Z.
    HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
  • [28] Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy
    Lavin, M.
    Brophy, T. M.
    Rawley, O.
    O'Sullivan, J. M.
    Hayden, P. J.
    Browne, P. V.
    Ryan, K.
    O'Connell, N.
    O'Donnell, J. S.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2016, 14 (06) : 1200 - 1205
  • [29] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    Leukemia, 2020, 34 : 3286 - 3297
  • [30] Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
    Plesner, Torben
    Arkenau, Hendrik-Tobias
    Gimsing, Peter
    Krejcik, Jakub
    Lemech, Charlotte
    Minnema, Monique C.
    Lassen, Ulrik
    Laubach, Jacob P.
    Palumbo, Antonio
    Lisby, Steen
    Basse, Linda
    Wang, Jianping
    Sasser, A. Kate
    Guckert, Mary E.
    de Boer, Carla
    Khokhar, Nushmia Z.
    Yeh, Howard
    Clemens, Pamela L.
    Ahmadi, Tahamtan
    Lokhorst, Henk M.
    Richardson, Paul G.
    BLOOD, 2016, 128 (14) : 1821 - 1828
12345